Clinical Trials Logo

Clinical Trial Summary

This phase II trial tests the effect of decreasing (tapering) doses of dexamethasone on steroid side effects in patients after surgery to remove (craniotomy) a brain tumor. Steroids are the gold standard post-surgery treatment to reduce swelling (edema) at the surgical site to reduce neurological symptoms. Although, corticosteroids reduce edema, they have side effects including high blood sugar, high blood pressure, and can impair wound healing. Dexamethasone is in a class of medications called corticosteroids. It is used to reduce inflammation and lower the body's immune response. It also works to treat other conditions by reducing swelling and redness. Tapering doses dexamethasone may decrease steroid side effects without increasing the risk of edema in patients with brain tumors after a craniotomy.


Clinical Trial Description

PRIMARY OBJECTIVES: I. The primary objective of this study is to evaluate the efficacy of a reduced dosage steroid schedule (RDS) in patients who have undergone craniotomy for high grade glioma (HGG), low grade glioma (LGG), brain metastasis (BM), and meningiomas as compared with the normal dosing schedule (NDS). II. RDS after undergoing craniotomy for brain tumor has no impact on length of stay, 30 day readmission, and need for repeat imaging when compared to NDS. SECONDARY OBJECTIVE: I. RDS after craniotomy for brain tumor has no impact on development of steroid related side effects (new onset or worsening hypertension, hyperglycemia, wound infection, impaired wound healing, steroid dependence, neuropsychiatric disturbance) when compared to NDS. TERTIARY/EXPLORATORY OBJECTIVE: I. RDS after craniotomy has no effect on lymphocyte count and differential at 10-14 days after surgery. OUTLINE: Patients are randomized to 1 of 2 arms. ARM I (NDS): Patients receive tapering doses of dexamethasone on days 1-15. Patients also undergo blood sample collection at time of surgery, at follow up visits and optionally at wound check visit 10-14 days post operative at investigator availability. Patients additionally undergo magnetic resonance imaging (MRI) and computed tomography (CT) scan during inpatient stay as part of standard of care. ARM II (RDS): Patients receive tapering doses of dexamethasone on days 1-4. Patients may receive dexamethasone intravenously (IV) and restart the taper if clinically indicated. Patients also undergo blood sample collection at time of surgery, follow up visits and optionally at wound check visit 10-14 days post operative at investigator availability. Patients additionally undergo MRI and CT scan during inpatient stay as part of standard of care. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06132685
Study type Interventional
Source Emory University
Contact Kimberly Hoang, MD
Phone 404-778-5770
Email kbhoang@emory.edu
Status Not yet recruiting
Phase Phase 2
Start date July 1, 2024
Completion date July 30, 2028

See also
  Status Clinical Trial Phase
Recruiting NCT04081701 - 68-Ga DOTATATE PET/MRI in the Diagnosis and Management of Somatostatin Receptor Positive CNS Tumors. Phase 4
Recruiting NCT03631953 - Combination of Alpelisib and Trametinib in Progressive Refractory Meningiomas Phase 1
Completed NCT03273712 - Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC) Phase 2
Recruiting NCT04367779 - Research of Biomarkers of Response to Proton Beam Therapy in Pediatric and Adult Patients.
Withdrawn NCT00985036 - Vascular Endothelial Growth Factor (VEGF) Levels in Brain Tumor Patients N/A
Completed NCT01347307 - Stereotactic Body Radiotherapy for Spine Tumors N/A
Completed NCT01811524 - The Etiology and Progression of Brain Tumors N/A
Completed NCT03648034 - Effects of Scalp Nerve Block With Ropivacaine on Postoperative Recovery Quality N/A
Recruiting NCT06036706 - Neurocognitive Impact of Different Irradiation Modalities for Patients With Grade I-II Skull Base Meningioma: N/A
Recruiting NCT06014905 - Feasibility of Acquiring Hyperpolarized Imaging in Patients With Meningioma Phase 1
Not yet recruiting NCT04386642 - Tranexamic Acid Reduce Blood Loss in Meningioma Resection Phase 4
Active, not recruiting NCT04595786 - The Safety of Intravenous Tranexamic Acid in Patients Undergoing Supratentorial Meningiomas Resection N/A
Completed NCT04305470 - Gleolan for Visualization of Newly Diagnosed or Recurrent Meningioma Phase 3
Completed NCT01967823 - T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer Phase 2
Not yet recruiting NCT02978677 - Proton Dose Escalation for Patients With Atypical or Anaplastic Meningiomas N/A
Active, not recruiting NCT02933736 - Ribociclib (LEE011) in Preoperative Glioma and Meningioma Patients Early Phase 1
Completed NCT02267928 - Information Presentation Formats N/A
Completed NCT00589784 - Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma Phase 2
Active, not recruiting NCT03071874 - Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas Phase 2
Recruiting NCT05416567 - Embolization for Meningioma N/A